
Emergent BioSolutions EBS
€ 7.73
-1.42%
Quartalsbericht 2026-Q1
hinzugefügt 23.05.2026
Emergent BioSolutions Operativer Cashflow 2011-2026 | EBS
Operativer Cashflow Jährlich Emergent BioSolutions
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 171 M | 58.7 M | -206 M | -34.1 M | 320 M | 537 M | 188 M | 41.8 M | 208 M | 54.6 M | 42.5 M | 112 M | 97 M | 39.6 M | 12.2 M | 98 M | 29.9 M | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 537 M | -206 M | 104 M |
Operativer Cashflow Vierteljährlich Emergent BioSolutions
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -33.8 M | 92.9 M | 95.2 M | -11.2 M | 139 M | -15.1 M | -62.6 M | - | -298 M | -184 M | - | - | - | -37.3 M | - | - | - | 5.1 M | - | 291 M | 186 M | 57.8 M | - | 65.9 M | 69 M | 105 M | - | 208 M | 33.6 M | -1 M | - | 131 M | 95.7 M | 41.7 M | - | 67.3 M | 40.2 M | - | - | - | - | -65.9 M | - | 60.5 M | -18.4 M | -29.2 M | - | 88.3 M | 28.2 M | -4.63 M | - | 78.7 M | 32.2 M | 13.8 M | - | -24.7 M | -29.4 M | -22.7 M |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 291 M | -298 M | 31.2 M |
Operativer Cashflow anderer Aktien in der Arzneimittelhersteller
| Name | Operativer Cashflow | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Endo International plc
ENDP
|
435 M | - | - | $ 28.9 M | ||
|
Evoke Pharma
EVOK
|
-5.46 M | - | - | $ 36.6 M | ||
|
HEXO Corp.
HEXO
|
-117 M | - | 2.45 % | $ 38.1 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
-435 M | - | -0.1 % | $ 2.03 B | ||
|
AcelRx Pharmaceuticals
ACRX
|
-11.4 M | - | 7.5 % | $ 6.35 M | ||
|
DURECT Corporation
DRRX
|
-19.1 M | - | - | $ 50.1 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
-25.9 M | - | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
-99.2 M | - | - | $ 754 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
4.93 M | $ 5.86 | 1.56 % | $ 87 M | ||
|
Agile Therapeutics
AGRX
|
-9.58 M | - | 10.11 % | $ 58.2 M | ||
|
Alimera Sciences
ALIM
|
-14.3 M | - | - | $ 142 M | ||
|
Cronos Group
CRON
|
25.9 M | $ 2.72 | -0.37 % | $ 1.04 B | ||
|
Athenex
ATNX
|
-131 M | - | -23.39 % | $ 1.76 M | ||
|
Harrow Health
HROW
|
43.9 M | $ 34.43 | 0.76 % | $ 1.27 B | ||
|
Avadel Pharmaceuticals plc
AVDL
|
-46.9 M | - | - | $ 2.06 B | ||
|
Catalent
CTLT
|
268 M | - | - | $ 11.5 B | ||
|
Eagle Pharmaceuticals
EGRX
|
50.7 M | - | -39.89 % | $ 27.7 M | ||
|
Bausch Health Companies
BHC
|
1.4 B | $ 5.39 | -0.19 % | $ 2 B | ||
|
Pacira BioSciences
PCRX
|
189 M | $ 24.04 | -1.31 % | $ 1.11 B | ||
|
Organogenesis Holdings
ORGO
|
-10.3 M | $ 2.66 | - | $ 337 M | ||
|
Canopy Growth Corporation
CGC
|
-166 M | $ 1.07 | 1.9 % | $ 115 M | ||
|
Solid Biosciences
SLDB
|
-156 M | $ 7.02 | 2.03 % | $ 614 M | ||
|
Aurora Cannabis
ACB
|
16 M | $ 3.47 | 0.29 % | $ 190 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
-88 K | $ 1.08 | 1.89 % | $ 1.34 M | ||
|
Jupiter Wellness
JUPW
|
-6.4 M | - | - | $ 33.6 M | ||
|
Tilray
TLRY
|
7.91 M | $ 5.55 | 1.83 % | $ 3.43 B | ||
|
Lannett Company
LCI
|
-7.12 M | - | 1.15 % | $ 7.11 M | ||
|
OrganiGram Holdings
OGI
|
3.87 M | $ 1.11 | - | $ 106 M | ||
|
Evolus
EOLS
|
-42.3 M | $ 6.18 | -1.12 % | $ 398 M | ||
|
Sundial Growers
SNDL
|
-155 M | $ 1.45 | 0.69 % | $ 3.37 M | ||
|
cbdMD
YCBD
|
-1.45 M | $ 0.77 | 0.66 % | $ 3.1 M | ||
|
Veru
VERU
|
-30 M | $ 2.33 | 0.87 % | $ 34.1 M | ||
|
Neoleukin Therapeutics
NLTX
|
-77.2 M | - | - | $ 193 M | ||
|
Assertio Holdings
ASRT
|
-28.2 M | $ 23.41 | -0.21 % | $ 150 M | ||
|
ProPhase Labs
PRPH
|
28.6 M | - | - | $ 5.07 M | ||
|
Radius Health
RDUS
|
-22.4 M | - | - | $ 1.42 B | ||
|
PetIQ
PETQ
|
61.9 M | - | 1.64 % | $ 400 M | ||
|
Relmada Therapeutics
RLMD
|
-45.8 M | $ 7.26 | 1.26 % | $ 287 M | ||
|
Recro Pharma
REPH
|
-1 M | - | -4.76 % | $ 65.3 M | ||
|
OptiNose
OPTN
|
-20.5 M | - | - | $ 1.08 B | ||
|
SCYNEXIS
SCYX
|
-5.28 M | $ 0.7 | 2.92 % | $ 35 M | ||
|
PLx Pharma
PLXP
|
-32.1 M | - | -27.8 % | $ 2.56 M | ||
|
Viatris
VTRS
|
2.32 B | $ 16.29 | 0.18 % | $ 19 B | ||
|
Zomedica Corp.
ZOM
|
-17.6 M | - | -0.21 % | $ 98 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
-23 M | - | - | $ 55.5 M | ||
|
Rockwell Medical
RMTI
|
-659 K | $ 0.76 | 1.14 % | $ 27.3 M | ||
|
Tricida
TCDA
|
-140 M | - | - | $ 3.25 M | ||
|
China Pharma Holdings
CPHI
|
148 K | $ 0.75 | -1.04 % | $ 3.22 M | ||
|
TherapeuticsMD
TXMD
|
-159 M | $ 2.11 | - | $ 24.4 M |